Sonolisib

Sonolisib (PX-866) is a experimental drug that has been shown to be an irreversible inhibitor of PI-3 kinase with efficacy when delivered orally. It is an analog of the natural chemical compound wortmannin. Sonolisib was put in a phase 1 clinical trial by Oncothyreon. The clinical development plan for sonolisib includes both standalone and combination therapy in major human cancers. In 2010, sonolisib was starting 4 phase II trials for solid tumors. The company gave an update on its phase 2 trials in Jun 2012. Phase 1 results (with docetaxel) published Aug 2013.
In July 2014 published results of a phase 2 trial (for NSCLC) concluded : "The addition of PX-866 to docetaxel did not improve PFS, response rate, or OS in patients with advanced, refractory NSCLC without molecular preselection". In Sept 2015 as Phase 2 trial for recurrent glioblastoma reported not meeting its primary endpoint.
Wikipedia contributors, "Sonolisib", Wikipedia, revision 1385705102, retrieved 20 November 2026, source, CC BY-SA 4.0.